Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019 08; 7(8):618-628.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal, Humanized
Cardiovascular Diseases
Diabetes Complications
Female
Humans
Male
Middle Aged

authors with profiles

Robert Harrington